Safinamide Reduced Inflammatory Pain in Rat Study

Researchers found that the medication decreased thermal sensitivity in animal models without affecting motor function.

Updated on Sept. 29, 2026 in Stroke

Isometric editorial illustration of geometric tissue and neural pathway structures, symbolizing biological pain signaling mechanisms. — Researchers identified that the medication safinamide reduces inflammatory pain signaling in laboratory models, potentially offering a path toward new pain management strategies. AI Illustration. Upload story photo >

Live Poll

Should research on existing drugs for new medical uses receive more focus and clinical funding?

A laboratory study found that safinamide, a medication currently used for other conditions, reduced signs of inflammatory pain in rats. The findings offer a preliminary look at how the drug might interact with pain-related inflammatory pathways.

Why it matters

This research explores a potential new application for an existing drug to manage inflammatory hyperalgesia. Understanding how such treatments affect neuroimmune responses could eventually help inform future research into novel pain management strategies.

In a preclinical study using 32 male Wistar rats, researchers evaluated the effects of safinamide on inflammatory pain and motor coordination. The drug successfully attenuated thermal hyperalgesia, though these findings are preliminary and have not been tested in humans.

The players

Nature.com

A prominent scientific publishing platform that hosts peer-reviewed research across various medical and health disciplines.

The details

The study examined how safinamide impacts dorsal root ganglion tissues, where the drug appeared to decrease the expression of NaV1.7, a protein associated with pain signaling. By reducing inflammatory markers such as TLR4, NF-κB p65, TNF-α, and IL-1β, the treatment helped mitigate the rats' hypersensitivity to thermal stimuli. Researchers confirmed the drug did not impair motor coordination or exploratory behavior using standardized behavioral assessments.

September 29, 2026: Findings were published on Nature.com.

Health Landscape

This study aligns with the broader scientific interest in targeting NaV1.7 channels to address chronic and inflammatory pain conditions. It represents an early exploration of repurposing established medications to modulate these specific pain-signaling pathways.

Because these results are based on an animal study, they do not change current clinical recommendations for pain management. Any concerns regarding persistent inflammatory pain or new treatment options should always be discussed directly with your physician.

The takeaway

This animal study suggests safinamide may help reduce pain-related inflammation by targeting specific protein pathways. Future research will be necessary to determine if these findings have any relevance to human health or clinical pain management.